soul trial oral semaglutide cardiovascular outcomes soul trial results Novo Nordisk's lowers MACE risk in The SOUL Study - by
Description
Phase Phase 4 - High escalation Weeks Weeks 13-16 Weekly dose 1.7 mg What to expect Approaching the weight-management dose
Doctors say its essential for patients to understand they could fall into either camp responder or non-responder even though the data suggests its more likely a person will respond
If you like food, then that pleasure is gone
Is There Any Chance of a Comeback
This dual action is intended to enhance metabolic control by targeting different aspects of glucose and lipid metabolism2
